Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Mar;61(3):315-20.
doi: 10.1111/j.1365-2125.2005.02566.x.

Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes

Masatomo Miura  1 , Hideaki Kagaya, Hitoshi Tada, Tsukasa Uno, Norio Yasui-Furukori, Tomonori Tateishi, Toshio Suzuki
Affiliations

Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes

Masatomo Miura et al. Br J Clin Pharmacol. 2006 Mar.

Abstract

Aim: Rabeprazole is metabolized to some extent by CYP2C19. The purpose of this study was to elucidate the pharmacokinetics of each rabeprazole enantiomer in three different CYP2C19 genotype groups.

Methods: Twenty-four healthy subjects, of whom each each were homozygous extensive metabolizers (homEMs), heterozygous extensive metabolizers (hetEMs) and poor metabolizers (PMs) for CYP2C19, participated in our study. After a single oral dose of 20 mg of racemic rabeprazole, the plasma concentrations of the rabeprazole enantiomers were measured over the course of 24 h.

Results: The area under the plasma concentration-time curves (AUC) of (R)-rabeprazole in homEMs, hetEMs and PMs were 1.8-, 2.2- and 2.4-fold, respectively, greater than those of (S)-rabeprazole; the relative AUC ratios of (R)- and (S)-rabeprazole in homEMs, hetEMs and PMs were 1:1.1:2.1 and 1:0.9:1.5, respectively. The mean maximum plasma concentrations (Cmax) of (R)-rabeprazole in homEMs, hetEMs and PMs were 1.7-, 1.9- and 1.8-fold higher, respectively, than those of the corresponding (S)-enantiomer (P<0.05). There was no difference between homEMs and PMs in the elimination half-life of (S)-rabeprazole, whereas the elimination half-life of (R)-rabeprazole was significantly longer in PMs than in homEMs [1.7 h (1.4, 2.0) (mean (95% confidence interval)]vs. 0.8 h (0.6, 1.0), respectively, P<0.0001).

Conclusions: (R)-Rabeprazole disposition was influenced to a greater degree by CYP2C19 genetic polymorphisms than was that of (S)-rabeprazole. The effect of CYP2C19 polymorphisms on the stereoselective disposition of rabeprazole was less than those of lansoprazole and omeprazole.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean ± SD plasma concentration–time profiles of (R)-rabeprazole (•) and (S)-rabeprazole (○) for A: homozygous extensive metabolizers (EMs); B: heterozygous EMs; and C: poor metabolizers, after a 20-mg oral dose of racemic rabeprazole
See this image and copyright information in PMC

References

    1. Prakash A, Faulds D. Rabeprazole. Drugs. 1998;55:261–7. - PubMed
    1. Morii M, Takata H, Fujisaki H, Takeguchi N. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlated with the rate of acid-activation of the inhibitor. Biochem Pharmacol. 1990;39:661–7. - PubMed
    1. Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol. 1991;42:321–8. - PubMed
    1. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13:27–36. - PubMed
    1. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther. 1995;58:143–54. - PubMed

Publication types

MeSH terms